Prolight Diagnostics publishes investor letter for October 2023

Prolight Diagnostics publishes an investor letter for October 2023. In the investor letter, an interview is given with Karl Bullen, COO at Prolight Diagnostics.

Link to investor letters:
https://prolightdx.com/en/mediaeng/investor-letters/

For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/

About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Investerarbrev 2 Okt 2023 Eng
Prolight Diagnostics publishes investor letter for October 2023

Investerarbrev 2 Okt 2023 Eng
Prolight Diagnostics publishes investor letter for October 2023
Back

Subscribe